{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:18:45Z","timestamp":1789543125331,"version":"build-2803163510"},"reference-count":55,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T00:00:00Z","timestamp":1346716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:p>Fan X, Borba CPC, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC. Metabolic effects of adjunctive aripiprazole in clozapine\u2010treated patients with schizophrenia.<\/jats:p><jats:p><jats:bold>Objective:\u2002<\/jats:bold>This study examined the effects of adjunctive aripiprazole therapy on metabolism in clozapine\u2010treated patients with schizophrenia.<\/jats:p><jats:p><jats:bold>Method:\u2002<\/jats:bold>In an 8\u2010week randomized, double\u2010blind, placebo\u2010controlled study, subjects received either aripiprazole (15\u2003mg\/day) or placebo. At baseline and week 8, metabolic parameters were assessed by the frequently sampled intravenous glucose tolerance test, nuclear magnetic resonance spectroscopy and whole\u2010body dual\u2010energy X\u2010ray absorptiometry (DXA).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold>Thirty subjects completed the study (16 in the aripiprazole group and 14 in the placebo group). Glucose effectiveness measured by the frequently sampled intravenous glucose tolerance test improved significantly in the aripiprazole group (0.003\u2003\u00b1\u20030.006 vs. \u22120.005\u2003\u00b1\u20030.007\/min,<jats:italic>P<\/jats:italic>\u2003=\u20030.010). The aripiprazole group showed significant reductions in both plasma low\u2010density lipoprotein (LDL) levels (\u221215.1\u2003\u00b1\u200319.8 vs. 4.4\u2003\u00b1\u200322.5\u2003mg\/dl,<jats:italic>P<\/jats:italic>\u2003=\u20030.019) and LDL particle numbers (\u2212376\u2003\u00b1\u2003632 vs. \u221236\u2003\u00b1\u2003301\u2003n<jats:sc>m<\/jats:sc>,<jats:italic>P<\/jats:italic>\u2003=\u20030.035). Further, there was a significant reduction in the lean mass (\u22121125\u2003\u00b1\u20031620 vs. 607\u2003\u00b1\u20031578\u2003g,<jats:italic>P<\/jats:italic>\u2003=\u20030.011) measured by whole\u2010body DXA scan in the aripiprazole group. All values were expressed as mean\u2003\u00b1\u2003standard deviation, aripiprazole vs. placebo.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold>Adjunctive therapy with aripiprazole may have some metabolic benefits in clozapine\u2010treated patients with schizophrenia.<\/jats:p>","DOI":"10.1111\/acps.12009","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T06:31:48Z","timestamp":1346740308000},"page":"217-226","source":"Crossref","is-referenced-by-count":57,"title":["Metabolic effects of adjunctive aripiprazole in clozapine\u2010treated patients with schizophrenia"],"prefix":"10.1111","volume":"127","author":[{"given":"X.","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. P. C.","family":"Borba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Freudenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,4]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0205"},{"issue":"14","key":"e_1_2_8_3_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852900025499","article-title":"Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization","volume":"10","author":"Masand PS","year":"2005","journal-title":"CNS Spectr"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.600"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.4.2.187"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01710.x"},{"key":"e_1_2_8_7_2","first-page":"157","article-title":"Clozapine and weight gain","volume":"55","author":"Umbricht DS","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.10.1821"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0514"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0407"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0905"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002066"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300027"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611417104"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.368"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/2647"},{"key":"e_1_2_8_17_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)38891-3","article-title":"Inverse agonist activity of atypical antipsychotic drugs at human 5\u2010hydroxytryptamine2C receptors","volume":"295","author":"Herrick\u2010Davis K","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2005.11.007"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.186.1.7"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000126970"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(91)90023-5"},{"issue":"18","key":"e_1_2_8_22_2","first-page":"47","article-title":"A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double\u2010blind study","volume":"65","author":"Mcquade RD","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00612.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0505"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000490"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116541"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.1.19"},{"key":"e_1_2_8_28_2","first-page":"171","article-title":"Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy","volume":"48","author":"Otvos JD","year":"2002","journal-title":"Clin Lab"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.01234.2003"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820080032005"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-3-642"},{"key":"e_1_2_8_32_2","first-page":"59","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation","volume":"7","author":"Kay SR","year":"1989","journal-title":"Br J Psychiatry Suppl"},{"key":"e_1_2_8_33_2","first-page":"343","article-title":"SAFTEE: a technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine J","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_8_35_2","first-page":"1172","article-title":"How to examine patients using the Abnormal Involuntary Movement Scale","volume":"39","author":"Munetz MR","year":"1988","journal-title":"Hosp Community Psychiatry"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-5-951"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.38.12.1512"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.42.11.1663"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051215"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01325.x"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.9.1018"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0438009100"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1439"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0165"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1990.70.4.1135"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.44.11.1345"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(01)03026-8"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.4.387"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.43.3.411"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05107yel"},{"key":"e_1_2_8_51_2","first-page":"228","article-title":"Lipid abnormalities in insulin resistant states","volume":"4","author":"Watson KE","year":"2003","journal-title":"Rev Cardiovasc Med"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-008-0059-2"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-004-0050-5"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0480"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.23"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.1022"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facps.12009","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.12009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T20:31:54Z","timestamp":1744057914000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acps.12009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,4]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/acps.12009"],"URL":"https:\/\/doi.org\/10.1111\/acps.12009","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,4]]}}}